These promising findings extended beyond glioblastoma, as NKG2D-ζ CAR T cells also demonstrated efficacy in acute myeloid leukemia (AML) and T cell acute lymphoblastic leukemia (T-ALL) (101), reinforcing the potential of NKG2D-directed CAR therapies in cancer immunotherapy. Here, KLRK1 is linked to acute myeloid leukemia.